UHRF1 and hepatocellular carcinoma: Celecoxib, a COX-2 inhibitor, reduced PGE2-induced UHRF1 expression in a miR-520d-dependent manner in HCC cells, suggesting that celecoxib might be potentially useful for HCC treatment.